Seres Therapeutics, Inc. Payments for Repurchase of Initial Public Offering
Seres Therapeutics, Inc. (MCRB) reported Payments for Repurchase of Initial Public Offering of $2.93 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2018-03-08
- Seres Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2015-09-30 was $780.00K.
- Seres Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2015-06-30 was $1.05M.
- Seres Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2015-03-31 was $1.10M.
- Seres Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2015 was $2.93M, a 256.64% increase from fiscal 2014.
- Seres Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2014 was $821.00K.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 9 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $780.00K derived: sum of 2 quarters · filed 2018-03-08 | $1.83M derived: sum of 3 quarters · filed 2018-03-08 | $2.93M 10-K · filed 2018-03-08 |
| 2015-09-30 | $780.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.83M derived: sum of 2 quarters · filed 2016-11-10 | $2.93M 10-Q · filed 2016-11-10 | $3.72M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $2.15M 10-Q · filed 2016-08-11 | $2.94M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2015-03-31 | $1.10M 10-Q · filed 2016-05-16 | $1.89M derived: sum of 2 quarters · filed 2017-03-16 | ||
| 2014-12-31 | $796.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $821.00K 10-K · filed 2017-03-16 | ||
| 2014-09-30 | $25.00K 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |